For example, histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) [45], interferon-beta [46], and aurora kinase inhibitor MLN 8237 [47] all can be combined with TRAIL to enhance cytotoxicity in melanoma, and these chemically different entities all can lead to the upregulation of DR5. The gene discussed is TNFRSF10B; the disease is melanoma.